Catalyst: Solid Business Model Propels Growth For This Buy And Build Pharma

Catalyst: Solid Business Model Propels Growth For This Buy And Build Pharma #Catalyst #Solid #Business #Model…

Lantern pharma investors see $168,418 in stock sales

Lantern pharma investors see $168,418 in stock sales#Lantern #pharma #investors #stock #sales

Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025

Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in…

™E Pharma Announces Convocation of the 2025 Annual General Meeting of Shareholders

™E Pharma Announces Convocation of the 2025 Annual General Meeting of Shareholders#Pharma #Announces #Convocation #Annual #General…

Why AstraZeneca May Be 2025’s Most Underrated Pharma Stock (NASDAQ:AZN)

This article was written by Follow With over two decades of dedicated experience in investment, Allka…

Novartis's SWOT analysis: pharma giant faces generic threats, eyes new growth

Novartis's SWOT analysis: pharma giant faces generic threats, eyes new growth#Novartis039s #SWOT #analysis #pharma #giant #faces…

UroGen Pharma: ODAC Decision Puts Drug Approval In Limbo, But It's Not Over, Either

UroGen Pharma: ODAC Decision Puts Drug Approval In Limbo, But It's Not Over, Either #UroGen #Pharma…

The Play On BridgeBio Pharma: Great Expectations For Attruby

The Play On BridgeBio Pharma: Great Expectations For Attruby #Play #BridgeBio #Pharma #Great #Expectations #Attruby

Pharma giant Regeneron to buy 23andMe and its customers’ data for $256M

Pharmaceutical maker Regeneron announced Monday it will buy genetic testing company 23andMe for $256 million following…

Innate Pharma S.A. 2025 Q1 – Results – Earnings Call Presentation

Innate Pharma S.A. 2025 Q1 – Results – Earnings Call Presentation #Innate #Pharma #S.A #Results #Earnings…

UroGen Pharma Ltd. (URGN) Q1 2025 Earnings Call Transcript

UroGen Pharma Ltd. (URGN) Q1 2025 Earnings Call Transcript #UroGen #Pharma #URGN #Earnings #Call #Transcript

Pharma stocks recover from initial shock of Trump's drug pricing order

Pharma stocks recover from initial shock of Trump's drug pricing order#Pharma #stocks #recover #initial #shock #Trump039s…

Asia pharma stocks tumble as Trump vows to slash US drug prices

Asia pharma stocks tumble as Trump vows to slash US drug prices#Asia #pharma #stocks #tumble #Trump…

Royalty Pharma: Again, Guidance Raised, Buy Confirmed

Royalty Pharma: Again, Guidance Raised, Buy Confirmed #Royalty #Pharma #Guidance #Raised #Buy #Confirmed

Paysign: Impressive Growth In Its Pharma Business

Paysign: Impressive Growth In Its Pharma Business #Paysign #Impressive #Growth #Pharma #Business

OKYO Pharma speeds up NCP drug development

OKYO Pharma speeds up NCP drug development#OKYO #Pharma #speeds #NCP #drug #development

Astellas Pharma Inc. (ALPMF) Q4 2024 Earnings Call Transcript

Astellas Pharma Inc. (ALPMF) Q4 2024 Earnings Call Transcript #Astellas #Pharma #ALPMF #Earnings #Call #Transcript

Zealand Pharma launches long-term incentive programs for Zealand Pharma's Board of Directors, Corporate Management and employees for 2025

Zealand Pharma launches long-term incentive programs for Zealand Pharma's Board of Directors, Corporate Management and employees…

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely…

U.S. steps up pharma, chip import probes; LVMH reports – what's moving markets

U.S. steps up pharma, chip import probes; LVMH reports – what's moving markets#U.S #steps #pharma #chip…

European pharma companies warn Trump's tariffs could expedite shift to US

European pharma companies warn Trump's tariffs could expedite shift to US#European #pharma #companies #warn #Trump039s #tariffs…

Pharma stocks up on US tariff exemptions but analyst flags a $46B import cost risk

Pharma stocks up on US tariff exemptions but analyst flags a $46B import cost risk#Pharma #stocks…